NCT07183852

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Vastra Gotaland Region · Other Government
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma

Conditions

• Metastatic Uveal Melanoma
• Metastatic Cutaneous Melanoma

Interventions

Type	Name	Description
DRUG	Autologous Tumor Infiltrating Lymphocytes (TIL)	Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion
DRUG	Melphalan	1 mg/kg, IV
DRUG	Interleukin-2	2 MIU, subcutaneous twice daily for up to 14 days.

Timeline

• Start date: 2026-03-01
• Primary completion: 2028-03-01
• Completion: 2033-03-01
• First posted: 2025-09-19
• Last updated: 2025-09-19